Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates
Advanced Science · 2024
DOI: 10.1002/advs.202306401 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Sooin Kim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul, 04107, Republic of Korea. Hauptthemen laut MEDLINE: Immunoconjugates. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic Science Research Program in Korea, Advanced Bio-interface Core Research Facility.
Abstract (Originalsprache)
Chemically modified proteins have diverse applications; however, conventional chemo‐selective methods often yield heterogeneously labeled products. To address this limitation, site‐specific protein labeling holds significant potential, driving extensive research in this area. Nevertheless, site‐specific modification of native proteins remains challenging owing to the complexity of their functional groups. Therefore, a method for site‐selective labeling of intact proteins is aimed to design. In this study, a novel approach to traceless affinity‐directed intact protein labeling is established, which leverages small binding proteins and genetic code expansion technology. By applying this method, a site‐specific antibody labeling with a drug, which leads to the production of highly effective antibody‐drug conjugates specifically targeting breast cancer cell lines is achieved. This approach enables traceless conjugation of intact target proteins, which is a critical advantage in pharmaceutical applications. Furthermore, small helical binding proteins can be easily engineered for various target proteins, thereby expanding their potential applications in diverse fields. This innovative approach represents a significant advancement in site‐specific modification of native proteins, including antibodies. It also bears immense potential for facilitating the development of therapeutic agents for various diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Sogang University, 35 Baekbeom-ro, Mapo-gu, Seoul, 04107, Republic of Korea.
- New Drug Development Center, Osong Medical Innovation Foundation, 123 Osongsaengmyeong-ro, Heungdeok-gu, Cheongju, Chungbuk, 28160, Republic of Korea.
- School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Republic of Korea.
- Department of Biomedical Sciences, Graduate School of Medical Science, Brain Korea 21 Project, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 03722, Republic of Korea.
ORCID-Profile: Hyun Soo Lee
Förderung
- Basic Science Research Program in Korea
- Advanced Bio-interface Core Research Facility
Zitieren
APA
Kim, S., Kim, S., Kim, S., Kim, N., Lee, S. W., Yi, H., Lee, S., Sim, T., Kwon, Y., & Lee, H. S. (2024). Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates. Advanced Science. https://doi.org/10.1002/advs.202306401
Vancouver
Kim S, Kim S, Kim S, Kim N, Lee SW, Yi H, et al. Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates. Advanced Science. 2024. doi:10.1002/advs.202306401
BibTeX
@article{Kim2024,
author = {Kim, Sooin and Kim, Sanggil and Kim, Sangji and Kim, Namkyoung and Lee, Sang Won and Yi, Hanbin and Lee, Seungeun and Sim, Taebo and Kwon, Yongseok and Lee, Hyun Soo},
title = {Affinity‐Directed Site‐Specific Protein Labeling and Its Application to Antibody‐Drug Conjugates},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202306401}
}
EUVIMED